Rachel B. Salit, MD

Assistant Member
Clinical Research Division

Education

National Institutes of Health, National Cancer Institute, Fellowship in Hematology/Oncology 2010
University of Maryland Medical Center, Residency in Internal Medicine 2007
Loyola University Stritch School of Medicine, 2004, MD
Duke University, 1996, BS in Psychology, Magna Cum Laude

Research Focus

As a member of the Umbilical Cord Blood Transplant (UCBT) research program, the goal of my research is to improve the long-term outcomes of UCBT in patients with hematologic malignancies. My research concentrates primarily on adults who are receiving reduced intensity conditioning regimens. I am looking at ways to reduce infections, prevent graft-versus-host disease and decrease relapse in this patient population and improve their long-term quality of life. Lastly, I am trying to extend cord blood as a donor source to patients with myeloproliferative diseases such as myelofibrosis.

Clinical Expertise

My clinical work focuses on bone marrow/stem cell transplantation. I see adult patients with hematologic malignancies including leukemia, lymphoma and multiple myeloma from the time they arrive for consideration for an autologous or allogeneic stem cell transplant. I also attend on the inpatient bone marrow transplant service at the University of Washington Medical Center, the outpatient allogeneic transplant service at the SCCA which follows patients for their first 100 days post transplant and I frequently staff the long term follow-up clinic. 

Current Studies

Protocol 2239: Transplantation of Unrelated Donor Umbilical Cord Blood in Patients with Hematological Malignancies Using a Reduced-Intensity Preparative Regimen: A Multi-Center Trial Coordinated by the FHCRC

Protocol 2666: Immune Reconstitution after Cord Blood Transplant

Protocol 2580: A Multi-Center, Phase III, Randomized Trial of Reduced Intensity(RIC) Conditioning and Transplantation of Double Unrelated Umbilical Cord Blood (dUCB) versus HLA-Haploidentical Related Bone Marrow for Patients with Hematologic Malignancies (FHCRC Protocol 2580).

Protocol 2372: Nonmyeloablative Hematopoietic Cell Transplantation (HCT) for Patients with Hematologic Malignancies using Related, HLA-Haploidentical Donors: A Phase II trial of Peripheral Blood Stem Cells (PBSC) as the Donor Source

Protocol 9033: JAK-2 Inhibitor Prior to Allogeneic Stem Cell Transplant for Patients with Primary and Secondary Myelofibrosis: A Prospective Study 

 



Related News

Related Labs & Projects

View all labs & projects >
file

Contact Information

Phone
(206) 667-1317
Fax
(206) 667-2324
Email
Additional contact

Mail Stop: D2-100